Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalent Inc
(NY:
CTLT
)
59.55
-0.26 (-0.43%)
Streaming Delayed Price
Updated: 12:55 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalent Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
February 11, 2024
Even more revenue is on the way from additional sales of Wegovy.
Via
The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
February 10, 2024
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.
Via
The Motley Fool
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
February 09, 2024
From
Catalent, Inc.
Via
Business Wire
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
February 09, 2024
The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory.
Via
Benzinga
Earnings Outlook For Catalent
February 08, 2024
Via
Benzinga
Why Catalent Stock Soared Today
February 05, 2024
Catalent has agreed to be acquired by Novo Nordisk's parent company.
Via
The Motley Fool
Earnings Scheduled For February 9, 2024
February 09, 2024
Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.
Via
Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
February 08, 2024
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.
Via
Benzinga
Can financial, healthcare, energy stocks rise as rates stay high?
February 08, 2024
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024.
Via
MarketBeat
Analyst Expectations For Catalent's Future
January 25, 2024
Via
Benzinga
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
February 07, 2024
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
February 06, 2024
Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry.
Via
InvestorPlace
Catalent Analysts Raise Their Forecasts Following Acquisition News
February 06, 2024
On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.
Via
Benzinga
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 06, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Novo Nordisk Stock Crushed the Market on Monday
February 05, 2024
The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition.
Via
The Motley Fool
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
February 05, 2024
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
February 05, 2024
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
February 05, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 05, 2024
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
What's Going On With Eli Lilly Stock Today?
February 05, 2024
Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound.
Via
Benzinga
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
February 05, 2024
Catalent stock is rising higher on Monday after the company announced a $16.5 billion cash acquisition deal for CTLT shares.
Via
InvestorPlace
Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday
February 05, 2024
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand
February 05, 2024
This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases.
Via
Benzinga
SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?
February 05, 2024
From
Johnson Fistel, LLP
Via
Business Wire
CTLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Catalent, Inc. Is Fair to Shareholders
February 05, 2024
From
Halper Sadeh LLC
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 05, 2024
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!
Via
InvestorPlace
Novo Holdings to Acquire Catalent
February 05, 2024
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast
January 26, 2024
From
Catalent, Inc.
Via
Business Wire
Catalent Commits to Reducing Greenhouse Gas Emissions by 2030
January 25, 2024
From
Catalent, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.